Please login to the form below

Not currently logged in
Email:
Password:

TMC435

This page shows the latest TMC435 news and features for those working in and with pharma, biotech and healthcare.

Janssen buys hepatitis C candidate from GSK

Janssen buys hepatitis C candidate from GSK

The company plans to start trials combining GSK2336805 with its non-nucleoside polymerase inhibitor TMC647055 and simeprevir (TMC435) - an NS3/4A protease inhibitor developed with Sweden's Medivir.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    BMS' daclatasvir is an NS5A replication complex inhibitor that is already under investigation in combination with several other therapies, including Tibotec's NS3 protease inhibitor simeprevir (formerly known as TMC435) and

  • Merck and Roche team up for hepatitis C studies

    BMS 650032, and Johnson &Johnson/Tibotec's TMC435, all of which are in phase III testing.

  • BMS and Tibotec plan all-oral hepatitis C regimen

    The therapy would combine BMS' daclatasvir (BMS-790052), an NS5A replication complex inhibitor, with Tibotec's NS3 protease inhibitor TMC435, which is partnered with Medivir. ... Tibotec is currently conducting two phase II trials for TMC435 in

  • Medivir buys BioPhausia

    Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market ... of TMC435.”.

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics